Adagene Inc. (ADAG): Price and Financial Metrics

Adagene Inc. (ADAG): $1.95

0.03 (+1.30%)

POWR Rating

Component Grades













Add ADAG to Watchlist
Sign Up

Industry: Biotech



in industry

ADAG Stock Price Chart Interactive Chart >

Price chart for ADAG

ADAG Price/Volume Stats

Current price $1.95 52-week high $7.96
Prev. close $1.93 52-week low $0.90
Day low $1.93 Volume 68,094
Day high $2.10 Avg. volume 48,083
50-day MA $1.37 Dividend yield N/A
200-day MA $1.83 Market Cap 84.67M

Adagene Inc. (ADAG) Company Bio

Adagene Inc. operates as a biotechnology company. The Company focuses on the development of antibodies to cancer patients. Adagene serves patients in the United States and China.

ADAG Latest News Stream

Event/Time News Detail
Loading, please wait...

ADAG Latest Social Stream

Loading social stream, please wait...

View Full ADAG Social Stream

Latest ADAG News From Around the Web

Below are the latest news stories about ADAGENE INC that investors may wish to consider to help them evaluate ADAG as an investment opportunity.

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses confirmed in multiple tumor types and continuous tumor shrinkage in cold tumors (e.g., MSS CRC) and anti-PD-1-resistant patients - - Dose expansion in combination with anti-PD-1 therapy ongoing at different dosing regimens - SAN DIEGO and SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Adagene Inc.

Yahoo | January 9, 2023

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update at the Biotech Showcase™ 2023, taking place January 9-11th in San Francisco, in parallel to the annual J.P. Morgan Healthcare Conference. Details of the event are as follows: Date:Mon

Yahoo | January 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Thursday!

William White on InvestorPlace | December 22, 2022

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC; liver cancer). The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and

Yahoo | December 16, 2022

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene’s board of directors (the “Board”) as an independent director. He will also serve as an audit committee member. Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimer’s Disease, Parkinson’s dis

Yahoo | November 21, 2022

Read More 'ADAG' Stories Here

ADAG Price Returns

1-mo 69.57%
3-mo 103.13%
6-mo 15.38%
1-year -72.06%
3-year N/A
5-year N/A
YTD 47.17%
2022 -83.58%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5955 seconds.